Clinical Study
Differential Effects in Cardiovascular Markers between High-Dose Angiotensin II Receptor Blocker Monotherapy and Combination Therapy of ARB with Calcium Channel Blocker in Hypertension (DEAR Trial)
Table 1
Patient characteristics at baseline.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Data are the meansSEM. BMI, body mass index; WC, waist circumference; DM, diabetes mellitus; Cr, creatinine; eGFR, estimated glomerular filtration rate; K, potassium; UA, uric acid; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; GA, glycoalbumin; ANP, atrial natriuretic peptide; BNP, brain natriuretic peptide; ARC, active renin concentration; UAE, urinary albumin excretion; SBP, systolic blood pressure; DBP, diastolic blood pressure; ABI, ankle-brachial index; CAVI, cardioankle vascular index; AI, augmentation index; IMT, intima-media thickness. |